近年来ADC市场高速增长,Frost & Sullivan预测2032年全球ADC市场将达1151亿美元。1月14日,药明合联拟以27.9亿港元收购东曜药业,以增强产能、丰富项目组合、扩大客户群,巩固市场地位。1月9日,宜联生物与罗氏就YL201项目达成独家许可协议,宜联生物将获5.7亿美元首付款及后续款项,YL201已显潜力,针对多种癌症的III期临床试验已启动,并获FDA突破性疗法认证。此外,...
Source Link近年来ADC市场高速增长,Frost & Sullivan预测2032年全球ADC市场将达1151亿美元。1月14日,药明合联拟以27.9亿港元收购东曜药业,以增强产能、丰富项目组合、扩大客户群,巩固市场地位。1月9日,宜联生物与罗氏就YL201项目达成独家许可协议,宜联生物将获5.7亿美元首付款及后续款项,YL201已显潜力,针对多种癌症的III期临床试验已启动,并获FDA突破性疗法认证。此外,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.